Comerica Bank Has $3.74 Million Position in Bio-Rad Laboratories, Inc. $BIO

Comerica Bank lowered its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 35.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 12,350 shares of the medical research company’s stock after selling 6,747 shares during the quarter. Comerica Bank’s holdings in Bio-Rad Laboratories were worth $3,742,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in BIO. Royal Bank of Canada increased its stake in shares of Bio-Rad Laboratories by 25.2% in the first quarter. Royal Bank of Canada now owns 30,310 shares of the medical research company’s stock valued at $7,382,000 after buying an additional 6,100 shares during the period. Goldman Sachs Group Inc. increased its position in Bio-Rad Laboratories by 45.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company’s stock valued at $25,575,000 after purchasing an additional 32,874 shares during the period. Empowered Funds LLC increased its position in Bio-Rad Laboratories by 14.8% during the 1st quarter. Empowered Funds LLC now owns 1,547 shares of the medical research company’s stock valued at $377,000 after purchasing an additional 199 shares during the period. Jane Street Group LLC increased its position in Bio-Rad Laboratories by 95.3% during the 1st quarter. Jane Street Group LLC now owns 37,383 shares of the medical research company’s stock valued at $9,105,000 after purchasing an additional 18,239 shares during the period. Finally, Cetera Investment Advisers increased its position in Bio-Rad Laboratories by 13.5% during the 2nd quarter. Cetera Investment Advisers now owns 2,192 shares of the medical research company’s stock valued at $529,000 after purchasing an additional 260 shares during the period. Institutional investors and hedge funds own 65.24% of the company’s stock.

More Bio-Rad Laboratories News

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Revenue/operational positives — Q1 revenue of $592.1M slightly beat the consensus (~$590M) and revenue was up ~1.1% year?over?year; the company still shows a strong net margin (~29%). These factors provide some support versus a pure earnings shock. MarketBeat Q1 Release
• Neutral Sentiment: Analyst action — Wells Fargo cut its price target from $320 to $290 but kept an “equal weight” rating; the new PT still implies upside versus the current share level, which moderates the negative read on the name. Benzinga
• Neutral Sentiment: Full earnings call transcript now available — details on segment drivers, margin commentary and near?term cadence are in the call and may clarify management’s guidance changes for investors. Earnings Call Transcript
• Negative Sentiment: EPS miss — Q1 EPS was $1.89, below consensus (about $1.97) and down from $2.54 a year earlier, a clear earnings disappointment that weighed on sentiment. Zacks
• Negative Sentiment: Guidance cut — Management trimmed its FY?2026 outlook, issuing revenue guidance of about $2.5B–$2.6B versus consensus nearer the top of that range; the company explicitly lowered its outlook, which is the main driver of the share decline. TipRanks

Bio-Rad Laboratories Stock Performance

Shares of BIO stock opened at $255.70 on Friday. The company has a market cap of $6.90 billion, a price-to-earnings ratio of 42.12 and a beta of 1.06. Bio-Rad Laboratories, Inc. has a 52 week low of $211.43 and a 52 week high of $343.12. The company has a quick ratio of 4.19, a current ratio of 5.62 and a debt-to-equity ratio of 0.16. The firm has a 50 day moving average of $277.81 and a 200-day moving average of $298.17.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $1.89 EPS for the quarter, missing the consensus estimate of $1.97 by ($0.08). The company had revenue of $592.10 million for the quarter, compared to analyst estimates of $589.91 million. Bio-Rad Laboratories had a return on equity of 3.52% and a net margin of 6.52%.The business’s quarterly revenue was up 1.1% compared to the same quarter last year. During the same period last year, the business earned $2.54 EPS. On average, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

BIO has been the subject of a number of recent analyst reports. Citigroup downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and decreased their target price for the company from $375.00 to $300.00 in a research report on Tuesday, April 7th. Wells Fargo & Company decreased their target price on shares of Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating for the company in a research report on Friday. Finally, Wall Street Zen downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. One analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $333.00.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.